Noradrenergic and specific serotonergic antidepressant
From Wikipedia, the free encyclopedia
Noradrenergic and specific serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants.[1] They are thought to act by noradrenergic autoreceptor and heteroreceptor antagonism combined with specific serotonergic antagonism. This results in increases in both noradrenergic and specific serotonergic transmission.
Examples of NaSSAs include:
- Mirtazapine (Remeron®, Zispin®, Avanza®, Norset®, Remergil®)
NaSSAs are said to have fewer side effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with Mirtazapine.[2]
[edit] See also
[edit] References
- ^ Kent J (2000). "SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression". Lancet 355 (9207): 911-8. PMID 10752718.
- ^ Fawcett J, Barkin R (1998). "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression". J Affect Disord 51 (3): 267-85. PMID 10333982. link
 |
This medical treatment article is a stub. You can help Wikipedia by expanding it. |
